Salt Lake City, Utah, USA – May 4–8, 2025

Seinda Pharmaceutical Corp. is pleased to announce that its abstract,“A Phase 2, Double-Masked, Randomized, Vehicle-Controlled Trial of SY201 in Dry Eye Disease in US”has been selected for an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025. The presentation will feature key findings from the Phase II trial of SY-201, a novel multi-modal peptide therapeutic for dry eye, and showcase the utility of a quantitative MMP9-POC test developed and manufactured by Seinda.

---

Oral Presentation Details

• Session: Dry Eye Clinical Aspects
• Title: A Phase 2, Double-Masked, Randomized, Vehicle-Controlled Trial of SY201 in Dry Eye Disease
• Presenter: Dr. Jing-Feng Huang, Founder & CEO, Seinda Pharmaceutical Corp.
• Date/Time: May 7, 2025 | 10:30 AM – 10:45 AM (local time)
• Location: Salt Lake City, Utah, USA

---

About SY-201: A DED Therapeutic with Novel Multi-Modal Mechanisms of Action (MOA) Targeting Underlying Ocular Surface Disease in DED

SY-201 is a peptide therapeutic designed to restore ocular surface integrity and homeostasis through multi novel MOA. In an 8-week, multicenter, double-masked, vehicle-controlled Phase II trial conducted across 10 U.S. sites, SY-201 demonstrated robust and consistent efficacy and excellent tolerability profile in patients with moderate to severe dry eye disease.

Key Highlights from the Study

• Clinically Meaningful Improvements in both signs and symptoms, including:
  • Total Corneal Fluorescein Staining (tCFS) and Central CFS (cCFS)
  • Eye Dryness (VAS), SANDE and SANDE Symptom Severity Scores
•  Rapid Onset of Action: Treatment effects by SY201 on cornea staining and symptoms may be seen as early as Day 7 and continued to improve over 60 days in SY201 dose groups, while Vehicle group did not improve over time.
• Large Response Rate: As much as -17 points in LS Mean Difference in 0.5% SY201 over Vehicle group was seen in SANDE symptom severity score; in more severe subgroup with tCFS ≥ 7.5 at baseline, 84.2% of subjects in 0.5% SY201 group (n=19) improved greater than -1.5 units of tCFS from baseline, while only 38.9% did in the Vehicle group (n=17).
• Excellent Tolerability: No reports of burning, blurring, stinging, or taste alteration. All treatment-related adverse events were mild.

---

Seinda’s MMP9-POC: Biomarker-Driven Innovation in DED

The study also incorporated MMP9-POC, Seinda’s quantitative tear biomarker point-of-care tests that measures MMP-9 levels in tears — a key inflammatory biomarker in DED.

Diagnostic Advantages

• High Sensitivity and Precision: Enables stratification of DED patients by inflammatory burden.
• Fast, Patient-Friendly Testing: Provides digital results in under 15 minutes, supporting real-time clinical decision-making.

---

Innovation for Healthier Eyes

Transforming eye care through precision medicine ― advancing next-generation diagnostics and therapies for healthier eyes and brighter futures.

“We are excited to present these proof-of-concept findings at ARVO 2025,”  said Dr. Jing-Feng Huang, Founder and CEO of Seinda. “The Novel multi-Modal MOA addresses underlying core mechanisms in restoring ocular surface integrity and homeostasis in DED, exhibiting efficacy outcomes with excellent tolerability profile of SY-201, combined with the diagnostic precision of our tear biomarker test, represent a transformative approach to dry eye disease management. We are committed to advancing SY-201 into phase 3 and NDA to address the unmet needs of millions living with DED.”

---

For more information, visit http://www.seindapharm.com or contact info@seindapharm.com